[Asia Economy Reporter Hyunseok Yoo] Shin Young Securities analyzed on the 19th that NewgLab Pharma is currently proving the value of KAT through the full-scale commencement of clinical trials for Korea's first metabolic anticancer agent in the United States. No investment opinion or target price was presented.
NewgLab Pharma was established in 2004 as a manufacturer and seller of CCTV cameras. In 2019, it pursued new drug development as a new business and changed its name to NewgLab Pharma this year. The drug pipeline under clinical trials includes ▲metabolic anticancer agent KAT-101 ▲ROS1/NTRT positive targeted anticancer agent Taletrectinib ▲oral COVID-19 treatment.
A metabolic anticancer agent refers to a drug that interferes with the metabolic activity of cancer cells, causing them to self-destruct. Researcher Myungseon Lee of Shin Young Securities said, "KAT-101 is being developed in both oral and injectable forms. Clinical trials started as monotherapy, but various studies such as combination therapy are possible," adding, "Phase 1/2a clinical trials in the US and Korea are planned to begin within this year."
The development of Taletrectinib, a targeted anticancer agent licensed in, and the oral COVID-19 treatment are also progressing smoothly. He explained, "The technology for Taletrectinib was introduced domestically from Anheart in the US, and Phase 2 clinical trials have been applied for patients with non-small cell lung cancer who take Zelcore or have resistance," adding, "Since Innovent Biologics in China has already announced positive interim results from Phase 2 clinical trials, the likelihood of clinical success is expected to be high."
He continued, "In addition, Phase 1 clinical trials for the oral formulation change of Nafamostat as a COVID-19 treatment have been completed, and results are expected to be announced within this year."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
